NATCOPHARMNatco Pharma Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)
₹950.65
▲ 0.60%Decent
Price & Volume
Loading chart…
Key Ratios
Market Cap (₹ cr)17,414.00
P/E12.28
P/B1.89
PEG—
ROE %16.85
ROCE %12.40
Debt / Equity0.08
EPS79.18
Revenue Growth %-39.60
Profit Growth %-34.10
Dividend Yield %0.52
Promoter Holding %50.99
FII Holding %12.37
DII Holding %—
Beta0.20
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
| Cup & Handle | LONG | 82% | ₹950.65 | ₹920.61 | ₹1,092.29 | 4.72 |
| Pullback to 21-EMA | LONG | 68% | ₹950.65 | ₹920.61 | ₹1,007.85 | 1.90 |
HOLDConviction 66%
The picture
- • ROE: 16.9%
- • Debt/Equity: 0.08
- • Promoter holding: 51.0%
- • MACD: bullish
- • Price vs EMA21: above
- • Price vs SMA200: above
- • Cup & Handle signal (setup quality 82%)
- • Pullback to 21-EMA signal (setup quality 68%)
Bull case
- • ROE: 16.9%
- • Debt/Equity: 0.08
- • Promoter holding: 51.0%
- • MACD: bullish
Bear case
- • Revenue growth: -39.6% YoY
- • Profit growth: -34.1% YoY
- • Price vs SMA50: below
- • 3-month return: -11.2%
Key risks
- • Revenue growth: -39.6% YoY
- • Profit growth: -34.1% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Entry (CMP)
₹950.65
Stop Loss
₹875.95
risk 7.9%
Target 1 (1.5R)
₹1,062.70
+11.8%
Target 2 (3R)
₹1,174.74
+23.6%
Support (20d)
₹884.80
Resistance (52w)
₹1,226.80
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹74.70/share
ATR (volatility)
₹30.04
avg daily range
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹30.04). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.
Score Breakdown
Fundamental
50
Technical
68
Momentum
50
Risk (safety)
59